MREO
Mereo BioPharma Group plc (MREO) Management Analysis (2026)
Overall Score
Capital Allocation
Balance sheet remains very liquid with a current ratio of 5.88 and cash ratio of 5.31.
Debt remains minimal with debt-to-equity at 0.04 and debt-to-assets at 0.03.
However, the company is still generating negative operating cash flow and free cash flow, limiting capital allocation flexibility.
No dividend is being paid, so capital returns are not a current support for the framework.
Management Execution
Profitability remains deeply negative, with ROIC at -1.11 and ROE at -0.75.
Operating returns are still negative, with operating ROA at -0.91 and ROA at -0.81.
Income quality is acceptable at 0.90, but it does not offset the lack of positive earnings or cash generation.
Management has not yet demonstrated sustained operating leverage or earnings conversion.
Strategic Discipline
The company continues to operate with a very small enterprise value relative to market cap, reflecting a distressed or highly speculative profile.
Working capital remains positive at 27.7M, but the business is not converting that into positive returns.
The absence of positive margins suggests strategy is not yet translating into scalable operating performance.
Net current asset value remains positive at 27.3M, providing some downside support but not evidence of strong strategic execution.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Mereo BioPharma Group plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

